title: [Clinical characteristics and efficacy analysis for patients over 55 years of age with acute lymphoblastic leukemia].
abstract: OBJECTIVE
  We investigated the clinical characteristics and therapeutic of elderly patients (≥55) with acute lymphoblastic leukemia (ALL).
  
  
  METHODS
  From Jenuary 2000 to July 2012, 45 elderly patients (≥55) were enrolled in the study. Patients assighed into CVDP VDP/VP induction chemotherapy based on organ function. Patients in complete remission (CR) undertake consolidation therapy, maintenance therapy or follow up. The patient who had appropriate donor received allogeneic hematopoietic stem cell transplantation (allo-HSCT). CR, Overall survival (OS), disease free survival (DFS), relapse rate and prognosis factors were analyzed.
  
  
  RESULTS
  45 elderly patients (≥55) about 9.6% in all 470 cases ALL simultaneity, and B-ALL about 88.9%. 27 patients (60%) obtained CR after 1 cycle of induction chemotherapy. 33 patients (73.3%) obtained overall CR. The CR rate significantly decreased in the elderly patients more than 60 years old vs. 55-60 years old patients (86.2% vs. 50%;P=0.009). All 45 patients 2 years OS rate was 33.7%, The median OS was 12 months (95%CI,6.68-17.32). 55-60 years (P=0.014), CR (P=0.002) and consolidation therapy (P=0.001) were independent favorite prognostic factors for OS. CVDP induction chemotherapy (P=0.013) and consolidation (P=0.049) were independent favorite prognostic factors for DFS.
  
  
  CONCLUSIONS
  The outcomes of elderly patients with ALL were poor, 55-60 years, CVDP induction chemotherapy, CR and consolidation therapy were independent favorite prognostic factors.
authors.affiliation: Institute of Hematology, People's Hospital of Peking University, Beijing 100044,China.
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.forename: Xiao-jun
authors.initials: XJ
authors.lastname: Huang
authors.forename: Bin
authors.initials: B
authors.lastname: Jiang
authors.forename: Qian
authors.initials: Q
authors.lastname: Jiang
authors.forename: Xi-jing
authors.initials: XJ
authors.lastname: Lu
authors.forename: Lan-ping
authors.initials: LP
authors.lastname: Xu
authors.forename: Dai-hong
authors.initials: DH
authors.lastname: Liu
authors.forename: Huan
authors.initials: H
authors.lastname: Chen
authors.forename: Li
authors.initials: L
authors.lastname: Bao
authors.forename: Jin
authors.initials: J
authors.lastname: Lu
authors.forename: Hong-hu
authors.initials: HH
authors.lastname: Zhu
authors.forename: Hao
authors.initials: H
authors.lastname: Jiang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D060830:Consolidation Chemotherapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D060828:Induction Chemotherapy; D060046:Maintenance Chemotherapy; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000628:therapy; D011239:Prednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D014750:Vincristine / Q000627:therapeutic use; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D003907:Dexamethasone; D003520:Cyclophosphamide; D011239:Prednisolone; D014751:Vindesine; D011241:Prednisone; D003630:Daunorubicin